🎉 M&A multiples are live!
Check it out!

Fresenius Valuation Multiples

Discover revenue and EBITDA valuation multiples for Fresenius and similar public comparables like Ramsay Health, Integral Diagnostics, and PureHealth.

Fresenius Overview

About Fresenius

Fresenius SE is a healthcare holding company based in Germany. The company owns a minority stake in dialysis service provider and equipment manufacturer Fresenius Medical Care. The Kabi segment manufactures intravenous drugs, nutrition products, infusion and transfusion therapies, and related pumps. The Helios segment operates private hospitals primarily in Germany and Spain.


Founded

1912

HQ

Germany
Employees

179.9K+

Website

fresenius.com

Financials

LTM Revenue $24.7B

LTM EBITDA $4.0B

EV

$39.3B

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 12K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Fresenius Financials

Fresenius has a last 12-month revenue (LTM) of $24.7B and a last 12-month EBITDA of $4.0B.

In the most recent fiscal year, Fresenius achieved revenue of $24.5B and an EBITDA of $3.5B.

Fresenius expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Fresenius valuation multiples based on analyst estimates

Fresenius P&L

LTM NTM Last FY FY 2025 FY 2026 FY 2027
Revenue $24.7B XXX $24.5B XXX XXX XXX
Gross Profit $6.0B XXX $6.0B XXX XXX XXX
Gross Margin 24% XXX 25% XXX XXX XXX
EBITDA $4.0B XXX $3.5B XXX XXX XXX
EBITDA Margin 16% XXX 14% XXX XXX XXX
EBIT $2.8B XXX $2.0B XXX XXX XXX
EBIT Margin 12% XXX 8% XXX XXX XXX
Net Profit $1.1B XXX $529M XXX XXX XXX
Net Margin 4% XXX 2% XXX XXX XXX
Net Debt XXX XXX $11.3B XXX XXX XXX

Financial data powered by Morningstar, Inc.

Fresenius Stock Performance

As of May 30, 2025, Fresenius's stock price is EUR 42 (or $48).

Fresenius has current market cap of EUR 23.9B (or $26.8B), and EV of EUR 35.0B (or $39.3B).

See Fresenius trading valuation data

Fresenius Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$39.3B $26.8B XXX XXX XXX XXX $3.60

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Fresenius Valuation Multiples

As of May 30, 2025, Fresenius has market cap of $26.8B and EV of $39.3B.

Fresenius's trades at 1.6x EV/Revenue multiple, and 11.1x EV/EBITDA.

Equity research analysts estimate Fresenius's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

Fresenius has a P/E ratio of 24.6x.

See valuation multiples for Fresenius and 12K+ public comps

Fresenius Financial Valuation Multiples

LTM NTM Last FY FY 2025 FY 2026 FY 2027
Market cap (current) $26.8B XXX $26.8B XXX XXX XXX
EV (current) $39.3B XXX $39.3B XXX XXX XXX
EV/Revenue 1.6x XXX 1.6x XXX XXX XXX
EV/EBITDA 9.7x XXX 11.1x XXX XXX XXX
EV/EBIT 13.8x XXX 19.6x XXX XXX XXX
EV/Gross Profit 6.6x XXX n/a XXX XXX XXX
P/E 24.6x XXX 50.7x XXX XXX XXX
EV/FCF 21.3x XXX 22.9x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Fresenius Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Fresenius Margins & Growth Rates

Fresenius's last 12 month revenue growth is 5%

Fresenius's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $22K for the same period.

Fresenius's rule of 40 is 18% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Fresenius's rule of X is 30% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Fresenius and other 12K+ public comps

Fresenius Operational Valuation Multiples

LTM NTM Last FY FY 2025 FY 2026 FY 2027
Revenue Growth 5% XXX 5% XXX XXX XXX
EBITDA Margin 16% XXX 14% XXX XXX XXX
EBITDA Growth 9% XXX 18% XXX XXX XXX
Rule of 40 18% XXX 20% XXX XXX XXX
Bessemer Rule of X XXX XXX 30% XXX XXX XXX
Revenue per Employee XXX XXX $0.1M XXX XXX XXX
Opex per Employee XXX XXX $22K XXX XXX XXX
S&M Expenses to Revenue XXX XXX 3% XXX XXX XXX
G&A Expenses to Revenue XXX XXX n/a XXX XXX XXX
R&D Expenses to Revenue XXX XXX 3% XXX XXX XXX
Opex to Revenue XXX XXX 16% XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Fresenius Public Comps

See public comps and valuation multiples for Hospitals & Clinics and Medical Supplies comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Burjeel Holdings XXX XXX XXX XXX XXX XXX
PureHealth XXX XXX XXX XXX XXX XXX
Integral Diagnostics XXX XXX XXX XXX XXX XXX
Ramsay Health XXX XXX XXX XXX XXX XXX
Athens Medical Centre XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Fresenius M&A and Investment Activity

Fresenius acquired  XXX companies to date.

Last acquisition by Fresenius was  XXXXXXXX, XXXXX XXXXX XXXXXX . Fresenius acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Fresenius

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Start Free Trial

About Fresenius

When was Fresenius founded? Fresenius was founded in 1912.
Where is Fresenius headquartered? Fresenius is headquartered in Germany.
How many employees does Fresenius have? As of today, Fresenius has 179.9K+ employees.
Is Fresenius publicy listed? Yes, Fresenius is a public company listed on ETR.
What is the stock symbol of Fresenius? Fresenius trades under FRE ticker.
When did Fresenius go public? Fresenius went public in 1992.
Who are competitors of Fresenius? Similar companies to Fresenius include e.g. Burjeel Holdings, PureHealth, Integral Diagnostics, Ramsay Health.
What is the current market cap of Fresenius? Fresenius's current market cap is $26.8B
What is the current revenue of Fresenius? Fresenius's last 12 months revenue is $24.7B.
What is the current revenue growth of Fresenius? Fresenius revenue growth (NTM/LTM) is 5%.
What is the current EV/Revenue multiple of Fresenius? Current revenue multiple of Fresenius is 1.6x.
Is Fresenius profitable? Yes, Fresenius is EBITDA-positive (as of the last 12 months).
What is the current EBITDA of Fresenius? Fresenius's last 12 months EBITDA is $4.0B.
What is Fresenius's EBITDA margin? Fresenius's last 12 months EBITDA margin is 16%.
What is the current EV/EBITDA multiple of Fresenius? Current EBITDA multiple of Fresenius is 9.7x.
What is the current FCF of Fresenius? Fresenius's last 12 months FCF is $1.8B.
What is Fresenius's FCF margin? Fresenius's last 12 months FCF margin is 7%.
What is the current EV/FCF multiple of Fresenius? Current FCF multiple of Fresenius is 21.3x.

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.